학술논문
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
Document Type
Article
Author
Source
In: The Lancet Rheumatology . (The Lancet Rheumatology, February 2021, 3(2):e101-e110)
Subject
Language
English
ISSN
26659913